T1	p 85 89	with
T2	p 216 259	44 patients with inclusion body myositis in
T3	i 90 115	methotrexate or placebo .
T4	i 154 182	week oral methotrexate could
T5	i 286 304	placebo-controlled
T6	i 525 537	methotrexate
T7	i 553 560	placebo
T8	i 840 852	methotrexate
T9	i 878 895	oral methotrexate
T10	o 20 40	weakness progression
T11	o 332 389	change of quantitative muscle strength testing sum scores
T12	o 428 486	. Quantitative muscle strength testing sum scores declined
T13	o 657 731	in manual muscle testing sum scores , activity scale scores and patients '
T14	o 778 818	Serum creatine kinase activity decreased
T15	o 914 944	progression of muscle weakness
T16	o 959 991	serum creatine kinase activity .